Observational study of antiphospholipid syndrome patients treated with direct oral anticoagulants
Part of Immune system & allergy clinical trials.
This study observes patients with antiphospholipid syndrome who are taking or have taken direct oral anticoagulants (blood thinners) to better understand their treatment experiences and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with antiphospholipid syndrome based on specific criteria.
- You are currently taking or have previously taken a direct oral anticoagulant (a type of blood thinner).
- You agree to allow your medical data to be used for research, without signing an opposition form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (DOACs like rivaroxaban or apixaban, and vitamin K blockers like warfarin) in people with antiphospholipid syndrome who had a vein clot. The goal is to see which one works better at preventing future clots without causing more bleeding.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
This study looks at whether patients taking certain blood-thinning medications (DOACs) have more bleeding during oral biopsies—small tissue samples taken from the mouth. Understanding this helps doctors know how to safely care for patients on these medications.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.